Prelude Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Prelude Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-126	Closed	-$9K	–	1646
2019 Q1	$9K	Buy	+126	New	+$7.41K	﹤0.01%	1457
2016 Q4	–	Sell	-1,858	Closed	-$123K	–	1528
2016 Q3	$123K	Buy	1,858 +284	+18%	+$17.8K	0.01%	746
2016 Q2	$88K	Buy	+1,574	New	+$76.5K	0.01%	808
2016 Q1	–	Sell	-1,200	Closed	-$54K	–	1242
2015 Q4	$54K	Buy	+1,200	New	+$51.7K	0.01%	1027
2015 Q3	–	Sell	-1,100	Closed	-$68K	–	1462
2015 Q2	$68K	Buy	1,100 +400	+57%	+$23.8K	0.01%	1036
2015 Q1	$44K	Sell	700 -700	-50%	-$42.6K	0.01%	1362
2014 Q4	$79K	Sell	1,400 -6,300	-82%	-$278K	0.01%	1087
2014 Q3	$218K	Buy	7,700 +6,351	+471%	+$190K	0.03%	679
2014 Q2	$46K	Sell	1,349 -800	-37%	-$25.1K	0.01%	1384
2014 Q1	$67K	Buy	+2,149	New	+$57K	0.01%	1180

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Prelude Capital Management's ANIP Position: Q2 2019 in Review

Prelude Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2019, closing a stake of 126 shares — an estimated $9K sold.

Prelude Capital Management first reported a position in ANIP in Q1 2014 and held it in 10 quarters. The position peaked at $218K in Q3 2014. 196 funds tracked by Wall St. Rank hold ANIP as of Q2 2019.

Prelude Capital Management reported no remaining ANI Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Prelude Capital Management sold 126 ANI Pharmaceuticals shares in Q2 2019, an estimated $9K.
Prelude Capital Management first reported a position in ANI Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Prelude Capital Management's ANI Pharmaceuticals position peaked at $218K in Q3 2014.
196 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2019.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.